Recent 8-K filings for SNSE
Highest-materiality recent filing
Sensei Biotherapeutics closes merger with Faeth and $200M PIPE; existing holders diluted to ~4.9%
- Issued ~10,602 Series B Preferred shares (each convertible into 1,000 common) to acquire Faeth; pre-PIPE: Faeth holders ~89.3%, Sensei ~10.7%.
- Sold 14,440 Series B Preferred shares in $200M PIPE; post-PIPE: PIPE investors ~54.3%, Faeth ~40.8%, Sensei ~4.9%.
-
Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.
-
Sensei Biotherapeutics Q1 net loss $170.2M; cash $202.8M; PIKTOR trial advances
Net loss of $170.2M ($131.45 per share) vs $6.9M loss a year ago, driven by $133.0M acquired IPR&D charge from Faeth acquisition.
-
Three Sensei directors to resign, new CEO & CFO conditional on stockholder approval
Christopher Gerry, Thomas Ricks, Kristian Humer resigning conditionally effective after June 10, 2026 annual meeting, contingent on stockholder approval of Conversion and Charter Amendment Proposals.
-
Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt
Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.
-
Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement
Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.
-
Sensei Biotherapeutics closes merger with Faeth and $200M PIPE; existing holders diluted to ~4.9%
Issued ~10,602 Series B Preferred shares (each convertible into 1,000 common) to acquire Faeth; pre-PIPE: Faeth holders ~89.3%, Sensei ~10.7%.
-
Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%
Discontinued solnerstotug development; Board considering sale, merger, or wind-down.
-
Sensei Biotherapeutics discontinues solnerstotug, initiates strategic review for sale or wind-down
Board discontinues development of solnerstotug after review of pipeline and market conditions.
-
6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.
-
Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end
Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).
-
Sensei Biotherapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter on July 2, 2025 confirming compliance with Rule 5550(a)(2).
-
Sensei Biotherapeutics announces 1-for-20 reverse stock split effective June 16
Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on June 16, 2025.
-
Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.
-
Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.
-
Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026
14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.75 · Most common event other_material